Human innate immune cells that “remember” previous stimulation could provide new insights into chronic inflammatory diseases.

T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting ...

By killing a certain proportion of actively dividing CAR-T cells, the secretion of inflammatory cytokines by chimeric T cells is reduced while retaining the efficacy of unaffected T cells. The Aveni ...

After encountering antigen in the periphery and under the influence of the cytokine milieu present, CD4 + T cells can further differentiate into subtypes, including Th1, Th2 and Th17. T cells seem ...

Researchers sought to determine whether CAR-T therapy would be effective in patients with RRMM and light chain amyloidosis.

Receiving CAR-T cell therapies in an outpatient setting may be safe and feasible without intensive remote monitoring with an early cytokine release syndrome (CRS) intervention strategy in patients ...

Notably, CAR T-cell-specific toxicities -- such as immune effector cell-associated neurotoxicity syndrome/neurotoxicity, cytokine release syndrome, and hemophagocytic lymphohistiocytosis -- were ...

Then, they injected mice with normal immune systems with the cytokine-containing liquid the cells were grown in. This treatment didn't trigger itchiness on its own. However, it did intensify the ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has ... the IL-2 pathway to activate tumor-specific T cells. Multiple groups have identified IL-2 as ...